Edgewise Therapeutics (EWTX) said Wednesday that the latest results from a phase 2 trial of EDG-7500 showed "rapid and clinically meaningful reductions" in left ventricular outflow tract gradients in participants with obstructive hypertrophic cardiomyopathy.
A four-week treatment with EDG-7500 also showed "substantial improvements" in measures of feel and function, as well as reductions in key cardiac biomarkers and positive trends in measures of diastolic function, the company said.
Edgewise said the initial data read-out from the study's part D is expected in H2 2025, while the phase 3 study is planned to begin in H1 2026.
Hypertrophic cardiomyopathy is a form of genetic heart disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。